Stifel Financial Corp Cuts Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Stifel Financial Corp cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 10.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 90,055 shares of the medical research company's stock after selling 10,538 shares during the period. Stifel Financial Corp owned about 0.18% of Charles River Laboratories International worth $16,624,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of CRL. Norges Bank bought a new stake in Charles River Laboratories International during the 4th quarter valued at $98,886,000. Wellington Management Group LLP boosted its position in shares of Charles River Laboratories International by 9.0% in the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Charles River Laboratories International in the 4th quarter worth $42,776,000. Invesco Ltd. boosted its position in shares of Charles River Laboratories International by 17.1% in the 4th quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company's stock worth $190,910,000 after purchasing an additional 151,159 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Charles River Laboratories International by 25.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 663,504 shares of the medical research company's stock worth $122,482,000 after purchasing an additional 135,986 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Insider Transactions at Charles River Laboratories International

In other news, COO Birgit Girshick bought 1,514 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at $9,064,198.54. The trade was a 2.83 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO James C. Foster purchased 6,075 shares of the business's stock in a transaction on Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on CRL. Barclays lowered their price target on Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Robert W. Baird reduced their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a research note on Thursday, February 20th. JPMorgan Chase & Co. cut their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research note on Thursday, February 20th. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price target for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. Finally, Morgan Stanley cut their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company's stock. According to MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and an average price target of $182.00.

Charles River Laboratories International Trading Down 1.4 %

Shares of CRL stock traded down $1.65 during trading on Thursday, hitting $116.97. 348,944 shares of the stock traded hands, compared to its average volume of 929,716. The firm has a market capitalization of $5.75 billion, a P/E ratio of 781.17, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The firm's fifty day moving average price is $143.94 and its 200-day moving average price is $169.71.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business's revenue was down 1.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.46 EPS. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).